RMD

Business profile & competitive position

ResMed Inc. (RMD) operates in the Healthcare sector, specifically the Medical – Instruments & Supplies industry. In plain terms, it designs and sells cloud-connected medical devices that treat sleep apnea and other breathing disorders—CPAP/APAP/bilevel/ventilation devices, masks, diagnostics, dental devices, and connected-care software. It also provides cloud-based Residential Care Software to home medical equipment providers, home health agencies, hospices, skilled nursing facilities, and senior living operators, with products sold in more than 140 countries.

The financial signature of this business points to a durable competitive position. ResMed’s net margin is 26.9% and its return on equity is 23.9%, figures that sit well above what commodity-like medical-supply businesses typically command. Those margins are supported by recurring revenue streams: masks, accessories, and diagnostics account for roughly 37% of the revenue mix, while software adds another 12%. Once a patient is onboarded onto a ResMed device, replacement masks, resupply, and remote-monitoring subscriptions tend to produce repeat revenue. The company’s installed base is large: as of its most recent 10-K filing, more than 35 million cloud-connected devices were feeding data into its AirView remote-monitoring platform, and more than 12 million patients were registered on the myAir patient-engagement app. That combination of hardware install base plus proprietary digital platforms creates a switching-cost dynamic that the margin and ROE numbers corroborate.

Financial posture

ResMed currently carries a market capitalization of $35.6 billion and trades at a trailing P/E of 24.2. Those valuation and profitability metrics are understandable in context: a 26.9% net margin and 23.9% ROE imply capital efficiency and pricing power, while a beta of 0.75 signals below-average market sensitivity. In other words, the market has tended to price this as a higher-quality, defensive healthcare compounder rather than a high-beta growth stock.

Within the revenue mix described in the 10-K, devices generated approximately 51% of fiscal 2026 net revenue, masks, diagnostics, and accessories around 37%, and software about 12%. That mix matters for earnings stability: devices are capital purchases that can be lumpy, while masks and software are steadier. The company also announced an agreement in June 2026 to sell its MatrixCare business for $490 million in cash; the transaction is expected to close in the first quarter of fiscal 2027. Management’s stated rationale is to sharpen the company’s focus on core sleep, breathing, and connected home-based healthcare.

Technically, the stock is at $253.025 with a 50-day EMA of $229.72 and an RSI of 77.5. The RSI above 70 simply notes that the shares have moved aggressively relative to their recent range heading into the October 2026 earnings report.

Strategic priorities & outlook

According to its most recent SEC 10-K filing, ResMed’s operational priorities center on four themes. First, it aims to grow and differentiate its core sleep apnea portfolio by integrating artificial intelligence and machine learning, simplifying care pathways, and expanding home diagnostics—highlighting products such as NightOwl and the VirtuOx IDTF acquisition. Second, it plans to accelerate market growth through awareness and education campaigns aimed at patients, physicians, and special-interest groups for sleep apnea, COPD, and related comorbidities.

Third, the company wants to capitalize on broader sleep and breathing-health adjacencies, including COPD, neuromuscular disease, and restless legs syndrome, with the Noctrix acquisition supporting that expansion. Fourth, it is investing in an integrated, intelligent digital-health ecosystem delivered at home, leveraging AirView remote monitoring and the myAir patient engagement platform. Supporting all of this is the pending divestiture of MatrixCare, which would make the company less of a pure software story and more focused on the sleep-and-breathing core.

Macro & geopolitical exposure

Because ResMed is classified in Healthcare / Medical – Instruments & Supplies, its principal macro exposures are those that affect medical-device manufacturers generally. Regulatory risk is at the top of the list: devices and software sold in the U.S. face FDA oversight, while international markets have their own notified-body and device-registration requirements. Any change in clearance timelines or post-market surveillance rules can alter launch schedules and compliance costs.

Reimbursement is another structural variable. Continuous positive airway pressure and related therapies depend heavily on payer coverage through Medicare, Medicaid, and private insurers. CMS decisions on durable medical equipment reimbursement or competitive bidding programs can move demand and pricing for device and mask sales.

Trade policy, currency, and supply chain also matter. The industry sources electronic components, semiconductors, and plastics globally, so tariffs, export controls, or shipping disruptions can affect cost structures. With sales in more than 140 countries, foreign exchange rates influence reported revenue and margins. Finally, public-health messaging around sleep apnea, obesity, and respiratory disease can expand or contract the addressable market over time.

Recent developments

Heading into the next report, earnings-focused coverage has dominated the headlines. On October 26, 2026, Zacks published “Why Investors Need to Take Advantage of These 2 Medical Stocks Now.” On October 23, 2026, two Zacks articles asked whether ResMed would beat estimates again and previewed the Q1 earnings release. Another Zacks piece on October 22, 2026, suggested earnings were expected to grow ahead of the following week’s report.

The stock is scheduled to report Q1 fiscal 2027 results on October 29, 2026, after the close. The current consensus EPS estimate is $2.69.

Earnings behavior & post-earnings drift

ResMed has established a strong earnings track record over the last eight quarters, beating analyst estimates in 7 of those 8 reports, an 88% beat rate, with an average earnings surprise of 3%. However, the average 5-day post-earnings price move across those quarters is just 0.24%, classified as flat drift.

The four most recent quarters underscore that gap between strong results and muted follow-through. On August 6, 2026, ResMed reported EPS of $2.95 against an estimate of $2.89, a 2.1% surprise, yet the stock fell 5.06% the next day and then rose 1.57% over the following five days. On April 30, 2026, EPS of $2.86 beat the $2.80 estimate by 2.1%, but the stock dropped 4.11% the next session and 3.24% over the next five days.

Earlier, on January 29, 2026, a 2.6% EPS surprise ($2.81 vs. $2.74 estimate) produced a modest 0.27% next-day gain and a stronger 3.66% five-day move. On October 30, 2025, EPS of $2.55 beat the $2.51 estimate by 1.6%, but the stock slid 2.13% the next day and 1.03% over the following five days. The pattern is consistent: ResMed has regularly exceeded the official consensus, but the market’s real expectation sometimes appears to be higher, and the next-day reaction has been negative more often than not.

Heading into the October 29, 2026 report, the unofficial consensus is $2.69, the RSI is 77.5, and the average post-report drift is effectively flat. Past beats do not guarantee future price direction.

For a deeper dive, readers should review the full institutional verdict, which aggregates detailed analyst models, price-target ranges, and post-report sentiment surrounding ResMed’s upcoming release.